A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers.
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2013
At a glance
- Drugs Beloranib (Primary)
- Indications Obesity
- Focus Adverse reactions; Biomarker
- 10 Jun 2012 Additional results were reported at the 72nd Annual Scientific Sessions of the American Diabetes Association, according to a Zafgen media release.
- 28 Jun 2011 Efficacy and cardiovascular tolerability results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2011 Cardiovascular data reported at the 71st Annual Scientific Sessions of the American Diabetes Association